By utilizing a specialized database, this study is ensuring the utmost safety and efficacy of the medication.

Monday morning pre-market screamer 😱 candidates: 🚨🚨🚨💎💎💎🔥🔥🔥 $TCBP Phase 2 update still pending-huge potential on this nano float $BOXD over $1 easy $ALLR PT $.50 $HTGM she’s ready for another big run This week was very good to me.

$BOXD now entering parabolic phase 🪐🚀🪐

Time-release formulations are associated with the added advantages of convenience of dosing, improved compliance, and less fluctuation in blood levels across the course of the day.

$BCRX In both the SAD and the MAD studies, oral BCX9250 was safe and well tolerated, with no serious adverse events, No safety signals were seen.

Nice and consistent for the median patient FYI the poster this chart is from notes that none of these patients are from the clinical trial

$BCRX so they hit their Q4 numbers, had stellar phase IA results and guided for a 70Mil increase in revenue in 202e.

$BCRX it’s a great time to be a BioCryst shareholder, oooup FDA clinical pause, hey we still have 9250, fda clinical lift, 9250 is too tough, 9930 is too tough…

A trial involving 450 children in Burkina Faso found that three doses of the vaccine, plus a booster shot, were up to 80 percent effective at preventing infection.

BCX10013 pre clinical may be impressive

$BCRX GSK: ANNOUNCES POSITIVE PHASE IIA STUDY RESULTS FOR A NEW FIRST-IN-CLASS CANDIDATE MEDICINE FOR PATIENTS WITH TUBERCULOSIS * GSK - TREATMENT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS IDENTIFIED

$BCRX $ATNM $ATNM positive Phase 3 for AML and only 24 million float!!

Management revenue growth product execution Great research team market competitiveness against it's competition size and future growth of market clinical trials BCRX is a 10 on all fronts

It reported positive outcomes in pleural mesothelioma patients, including: Improved survival: Study patients lived around 11 months.

PROC data are excellent compared to any combo trials.

But yesterdays paper also has me considering, if there isn't a deal with $mrk or $BMY or some other CPI BP --- That data is Best In Class - best in clinic, best in trial too.

phase II results within weeks!!!

Now phase 3 trial is showing similar results to date where patients are living longer after Galinpepimut-S up to 1.5 year longer is a breakthrough for AML patients.

Positive trial data/results supported with bullish news and sentiment! 4.

The nation’s best means the O'Neal Comprehensive Center in Alabama have access to the latest therapies, cutting-edge clinical trials and the expertise needed to treat their cancer.

Gps is doing what it has done in every single trial and its the reason Patients are living 3 fold longer than patients on best available treatments.

Treatment with GFH009 resulted in 90 to 100 percent cancer inhibition at dose levels equivalent to those already demonstrated to be safe in patients in the ongoing Phase 1 trial with no viable cancer cells at the highest dose levels.